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INTRODUCTION
Autism spectrum disorders (ASD) is a group of lifelong 
neurodevelopmental disorders characterized by impairment in 
social interaction and communication, delayed and disordered 
language, restricted and stereotypic patterns of behaviour, 
interests and activities, and onset before 3 years of age. They 
are classified according to ICD 10 (1) (Table 1).
 Autism spectrum disorders continue to increase at an 
alarming rate with the most recent statistics released by the 
Centers for Disease Control (CDC) indicating an incidence 
of 1.14%, or one in every 88 neurotypical children (2). Its 
ethiopathogenesis is poorly understood. Although a genetic 
origin has been recognized, it has been hypothesized a role for 
environmental factors, immune dysfunctions, and alterations 
of neurotransmitter systems. Sex-bias of ASD has a male to 
female ratio of approximately 4:1 (3). Recent findings from 
a study of more than 6 million ASD patients indicate that the 
prevalence of ASD seems to be increasing linearly from year 
to year (4). 
 The neurobiological basis for autism remains elusive. A 
variety of findings suggest disturbances of brain development 
as a key feature of pathophysiology (5). Recent studies show 
that the abnormal levels of neurotrophins, such as nerve growth 
factor (NGF), brain-derived neurotrophic factor (BDNF) and 
their relatives, might represent one of the aspects implicated 
in the pathogenesis of ASD (5-7). Studies on infants suggest 
that babies later diagnosed with ASD have smaller brain size 
at birth but undergo a rapid increase in brain volume during 
the first years of their life (8, 9). It has been hypothesized that 
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Table 1. F84 Pervasive developmental disorders 
F84.0  Childhood autism 
F84.1  Atypical autism 
F84.2  Rett’s syndrome 
F84.3  Other childhood disintegrative disorder 
F84.4   Overactive disorder associated with mental 
retardation and stereotyped movements 
F84.5  Asperger’s syndrome 
F84.8  Other pervasive developmental disorders 
F84.9  Pervasive developmental disorder, unspecified 
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the formation of neuronal connections and the elimination 
of inappropriate connections happens not in a physiological 
manner. Neuropathological studies on ASD show smaller 
neuronal sizes, decreased dendritic branches and alterations in 
dendritic spine density and shape in cortical projection neurons 
(10). Likewise, increased inhibitory synaptic transmission 
(11) and decreased Purkinjie cells in vermis and hemispheres 
of the cerebellum (12). There are some dysregulations also in 
the reelin, a glycoprotein secreted by neurons that is critically 
involved in the corticogenesis (13). Reelin also promotes 
maturation of dendrites and dendritic spines (14). Some aspects 
of the relationship between developmental dendritic pruning 
and elevated mTORC1 signaling (15), and macroautophagy 
in ASD have been recently demonstrated (4).
 To make the dance even more complicated, considerable 
attention has been recently centred upon the functionality 
and plasticity of glial cells, particularly astrocytes (16). 
These cells participate in normal brain development and 
also in neuropathological processes.  Data from an ASD 
animal model highlights that the astrocytic clearance and 
destination of glutamate in the synaptic cleft in tripartite 
synapses might be altered in autism, pointing out important 
aspects to be considered from both pathophysiologic and 
pharmacological approaches in ASD (17). The evidence 
also implicates dysfunctional signaling via Ca2 +-dependent 
mechanisms, extracellular signal-regulated kinases (ERK)/
phosphatidylinositol-3-kinases (PI3K) and neuroligin–
neurexin–SHANK as convergent molecular mechanisms in 
ASD (14). 
 Whatsoever, the molecular mechanisms underlying these 
changes are yet not fully understood. As mentioned above, 
neurothrophic factors are one of the most prominent vectors 
influencing the development and maintenance of the central and 
peripheral nervous system. They are a family of proteins that 
induce the survival, development, and function of neurons. 
They exert a key role in brain development and maintenance 
of neurons and are able to critically influence the formation and 
elimination of neuronal connections. Given these properties 
they have been recently discussed as promising candidates 
playing a role in autism pathobiology and being responsible 
at least partially for the alterations in ASD (5-7).
 The neurotrophin family of proteins consists of NGF, pro-
NGF, BDNF, pro-BDNF, neurotrophin-3 (NT-3), NT-4/5, 
NT-6, NT-7 (18). Here we will dance round all these factors. 
Besides the neurotrophins, there are other protein families 
exerting neurotrophic actions, such as glial cell line-derived 
neurotrophic factor (GDNF), ciliary neurotrophic factor 
(CNTF) and insulin-like growth factors (IGF), which are out 
of the scope of present Dance round. 
NGF
It has been hypothesized that abnormal levels of serum NGF 
may represent a serological marker for autistic children who 
may develop cognitive impairment, regression and finally 
epilepsy. The objective of a preliminary study was to measure 
serum NGF concentrations of autistic children and compare 
these levels with those of healthy children (19). Consecutive 
children who were referred to a pediatric unit  were 
investigated and serum samples analyzed for NGF levels. 
Forty-nine autistic children and an equal number of healthy 
children (control group) were included in the study.  Serum 
NGF concentrations were significantly higher in the study 
group compared with the control group. This preliminary 
findings suggested that enhanced serum NGF concentration 
could be used as a potential diagnostic tool in ASD. 
 In another study with rats, where a model of maternal 
infection was simulated, NGF expression was significantly 
increased in neonatal cortex, which was speculated to 
represent a potential mechanism through which maternal 
infection increased the risk for neurodevelopmental disorders 
(20). In a third study the level of NGF plasma levels 
were lower in patient with Rett syndrome with prolonged 
corrected QT interval in comparison with those with the 
same syndrome but normal QT (21). On the other hand, a 
previous study (22) detected normal levels of NGF in the 
cerebrospinal fluid in autism and low to negligible levels in 
Rett syndrome, which was in agreement with the different 
morphological and neurochemical findings (brain growth, 
affected brain areas, neurotransmitter metabolism) in the 
two syndromes. A suggestion was made to use cerebrospinal 
fluid NGF as a biomarker for differentiation of patients with 
autism from those with Rett syndrome.
 In another study the level of autoantibodies  to nerve 
growth factor was evaluated in blood serum of 163 children 
with different forms of mental dysontogenesis of different 
origin (23). Significant elevation of the level of autoantibodies 
was found in all forms of psychic dysontogenesis. The 
most significant elevation of the level of  autoantibodies, as 
compared with the controls (45 children), was characteristic 
for endogenic forms of dysontogenesis (schizophrenia, 
early children’s autism, schizotypic diathesis). The level of 
autoantibodies was also found as an indicator of the acuteness 
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of the pathologic state. Besides, its elevation was observed 
1-2 weeks prior to the onset of the clinical exacerbation.
BDNF
In a commonly used animal model of autism a transient 
increase of both mRNABDNF and BDNF protein levels was 
detected in the embryonic mouse brain (24). This model was 
created by the administration of valproic acid to pregnant 
animals at gestational days 12.5 (E12.5) or E13.5 which 
leads to autistic-like symptoms in the offspring. Of the 
nine 5’-untranslated exons of the mouse BDNF gene, only 
expression of exons I, IV and VI was stimulated by valproic 
acid in utero. The conclusion of the study was that in light of 
the well-established role of BDNF in regulating neurogenesis 
and the laminar fate of postmitotic neurons in the developing 
cortex, an aberrant increase in BDNF expression in the fetal 
brain may contribute to valproic acid-induced cognitive 
disorders by altering brain development.
 BDNF elevation in newborn blood serum was found to 
predict intellectual/social developmental abnormalities. Thus, 
the circulating BDNF levels and IgG/IgM autoantibodies 
to BDNF were measured in children with autism, healthy 
children, and children with non-neurological illness (25). Mean 
BDNF levels were elevated in children with autism  compared 
to healthy or children with non-neurological illnesses. Mean 
IgG and IgM BDNF autoantibodies were significantly elevated 
in children with autism compared to healthy children but not to 
children with non-neurological illness. The conclusion of the 
study was that children with autism have higher autoantibodies 
to BDNF compared to controls. The presence of both BDNF 
autoantibodies and elevated BDNF levels in some children 
with autism suggests a previously unrecognized interaction 
between the immune system and BDNF.
 Although this observation is in harmony with results from 
other studies showing high concentrations of BDNF in autistic 
children (26), in another study the opposite result is reported 
(27). The level of serum BDNF was investigated as well as 
its age-related changes in healthy controls in comparison to 
autistic subjects. The concentration of BDNF was measured 
after its gradual released from platelets at 4̊ C. In healthy 
controls, the serum BDNF concentration increased over the 
first several years, then slightly decreased after reaching the 
adult level. There were no sex differences between males and 
females. In the autism cases, mean levels were significantly 
lower in children 0–9 years old compared to teenagers or 
adults, or to age-matched healthy controls, indicating a delayed 
BDNF increase with development.
 In another study (28), subjects were recruited from a 
hospital in the Netherlands - 37 ASD patients [age around 
10 years; body mass index (BMI) = 18.0 ± 3.7 kg/m2] and 37 
controls (age around 10 years; BMI = 17.6 ± 3.0 kg/m2). It 
has been noted that there were not any age-related changes in 
the serum levels of BDNF as in other studies (27). 
 In a population of Chinese children aged around 4 years the 
potential role of BDNF was explored (29). Level of BDNF was 
assayed with enzyme-linked immunosorbent assay methods, 
and severity of ASD was evaluated with the Childhood 
Autism Rating Scale (CARS) Score. The results indicated 
that the median serum BDNF levels were significantly 
higher in children with ASD as compared to normal cases. 
The investigators found that an increased risk of ASD was 
associated with BDNF levels more than 15.0 ng/ml. This 
study demonstrated that serum BDNF levels were associated 
with ASD in a Chinese population, and higher levels could be 
considered as an independent contributing factor for ASD.
 Differences in the analytic platforms used in the above cited 
studies, assay and sample test methods, and subject populations 
may explain the inconsistencies among studies (30, 31). 
Furthermore, circadian and/or seasonal and sex dependent 
changes in the level of BDNF is recognized in some studies 
(27, 32-34).
NEUROTROPHINS-3, -4/5
A paucity of cerebellar Purkinje cells and abnormalities in 
the inferior olive are among the best-documented changes in 
brain structure in autism (12). NT-3 plays an important role in 
glutamatergic synapse development in vitro (35) and this could 
be a mechanism influencing brain development in autism.
Valproic aicd exposure in utero (in a rat model of autism) 
induced small increases in the expression of mRNANT-3 
(2.5-fold)  and  mRNANT-4/5 (2-fold)  (24). Expression of the 
neurotrophin receptors, TrkA, TrkB and TrkC were minimally 
affected, while levels of the low-affinity panneurotrophin 
receptor, p75NTR, doubled. In contrast to this investigation, 
in a study of Nelson et al (31), using a double-antibody 
immunoaffinity assay (Luminex) and ELISA technology, 
the  concentrations of certain neurotrophins  was measured 
in pooled samples eluted from archived neonatal blood of 
children with later diagnosed autism, Down syndrome, very 
preterm birth, or term control infants. Concentrations in control 
subjects differed by age: BDNF rose markedly with age, while 
NT-3 and NT-4/5 concentrations were lower in adults than in 
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Table 2. A summary of the studies on neurotrophobiology of autism spectrum disorders 
Neurotrophin Target population Sample used Main findings Reference
NGF Autistic and healthy children Blood serum ↑ serum level of NGF in autistic compared to 
healthy children
19
NGF Neurodevelopmental disorders Neonatal 
cortex
Increased expression 20
NGF Rett syndrome with prolonged 
corrected QT interval
Plasma ↓ Serum level of NGF compared with Rett 
syndrome with normal corrected QT interval
21





mental dysontogenesis of endogenic, 
residual-organic, psychogenic and 
deprivative origin





autistic spectrum disorders, mental 
retardation without autism  and 
cerebral palsy, and control children
Neonatal 
blood
No significant changes 7
BDNF Offsprings in an animal model of autism Brain ↑BDNF 5–6-fold 24
BDNF Children with autism, childhood 
disintegrative disorder, healthy children, 
non- neurological illnesses
Blood serum ↑ in autism and disintegrative disorders 
compared to healthy children and non- 
neurological illnesses
25
Ig G, Ig M BDNF 
autoantibodies
Children with autism, childhood 
disintegrative disorder, epilepsy, healthy 
children, non- neurological illnesses, 
epilepsy
Blood serum ↑ in autism, disintegrative disorders and 
epilepsy compared to healthy children and 
non- neurological illnesses
25
BDNF Pregnant women, children with 
autism, mental retardation and typical 
development
blood No change in mid-pregnancy and neonatal 
specimens 
30




Circadian but not seasonal changes. 
 ↓ in autistic children 0–9 years old compared 
to teenagers or adults, or to age-matched 
healthy controls
27
BDNF, NT-4 autism and mental retardation, or 
healthy controls 
Blood serum ↑ BDNF in autistic group (and the mental 
retardation compared to the control group.
↑ serum NT-4 concentration in the mental 
retardation group
6
BDNF ASD and controls Blood serum No age dependent changes 28
BDNF ASD and controls Blood serum ↑ in autistic children 29
NT-3, NT-4/5 autism, Down syndrome, very preterm 




↓ NT-3, NT-4/5 in autistic children compared 
to controls
31
IGF-1,-2 Autism and controls CSF ↓ IGF-1 in autistic children compared to 
controls, IGF-2 no difference between groups
37





Male rats in an animal model of autism Hippocampus unchanged at day 15




activity   
Male rats in an animal model of autism Hippocampus ↑ 43% at day 15 




Male rats in an animal model of autism Hippocampus unaltered at day15 
↑27%  at day 120
17
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newborn infants. In samples from autistic subjects, NT-3 levels 
were significantly lower than controls and an increase in VIP 
approached statistical significance. Concentrations of NT-4/5 
were correlated in infants with autism but not in controls. Some 
of these results differ from earlier findings using a single-
antibody recycling immunoaffinity chromatography (RIC) 
system. The mean concentration of NT-3 tended to be lower in 
children with later-diagnosed autism than in control subjects. 
The difference was of borderline statistical significance. 
Values for NT-4/5 did not distinguish children with autism 
from control infants. Thus measurement by Luminex again 
did not confirm the previous observations by RIC (7). There 
were no changes again in the level of NT-4/5 also in another 
study, in which the BDNF level was markedly increased (6). 
Meanwhile, for the possible involvement of insulin-like growth 
factor-I (IGF-I) in the development of autism, see (36, 37). 
CODA
The present Dance round demonstrates that blood serum and/
or cerebrospinal fluid levels of the neurotrophins NGF, BDNF, 
NT-3 and NT-4/5 may be associated with the pathogenesis of 
ASD (Table 2). Indeed, much more research is necessary in 
order to draw final conclusions about the possible link between 
the amount of neurotrophins and ASD in different population 
and age groups, and the methodology and biological samples 
which could be used for this purpose.
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